Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
Cancer and stromal cells actively exert physical forces (solid stress) to compress tumour blood vessels, thus reducing vascular perfusion. Tumour interstitial matrix also contributes to solid stress, with hyaluronan implicated as the primary matrix molecule responsible for vessel compression because of its swelling behaviour. Here we show, unexpectedly, that hyaluronan compresses vessels only in collagen-rich tumours, suggesting that collagen and hyaluronan together are critical targets for decompressing tumour vessels. We demonstrate that the angiotensin inhibitor losartan reduces stromal collagen and hyaluronan production, associated with decreased expression of profibrotic signals TGF-β1, CCN2 and ET-1, downstream of angiotensin-II-receptor-1 inhibition. Consequently, losartan reduces solid stress in tumours resulting in increased vascular perfusion. Through this physical mechanism, losartan improves drug and oxygen delivery to tumours, thereby potentiating chemotherapy and reducing hypoxia in breast and pancreatic cancer models. Thus, angiotensin inhibitors —inexpensive drugs with decades of safe use — could be rapidly repurposed as cancer therapeutics. Hyaluronan is a component of the tumour extracellular matrix. Here, Chauhan et al. show that hyaluronan increases blood pressure in collagen-rich tumours by compressing vessel walls, and that reducing the level of hyaluranon with an angiotensin II inhibitor increases blood flow and drug penetrance in tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, antiangiogenic drugs have a synergistic antitumor effect in combination with radiotherapy and chemotherapy in clinical practice.”
From Hypoxia signaling in cancer: Implications for therapeutic interventions (2023) · cites this paper as [260]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increased mechanical stress can collapse blood vessels, leading to hypoxia, thereby promoting more aggressive cancer phenotypes, and reducing drug delivery89,100–105.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [101]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“We have also shown that widely prescribed ARBs can normalize the stroma and decompress blood vessels, thereby improving the outcome of chemotherapy94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
In the citing paper
“results from our laboratory have shown that the elevated levels of extracellular matrix molecules, including collagen I and hyaluronan, in such tumours can compress blood vessels, impairing their function and resulting in hypoxia94.”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [94]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195 · cited 1×
“Hyaluronan has been proposed to be the primary matrix molecule responsible for vessel compression 12 , but its exact mechanism remains unclear.”
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
DeNardo, D. G., Brennan, D. J., Rexhepaj, E., Ruffell, B., Shiao, S. L., Madden, S. F., Gallagher, W. M., Wadhwani, N., Keil, S. D., Junaid, S. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8274.cd-10-0028 · Cited by 1,715 · cited 1×
“This might be attributed to resistance induced by the immune microenvironment 39 .”
Helmlinger, G., Yuan, F., Dellian, M., & Jain, R. K. (1997) · Nature Medicine · doi:10.1038/nm0297-177 · Cited by 1,628 · cited 2×
“We then studied oxygenation using phosphorescence quenching microscopy 35 .”
Self-citationNormalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248 · cited 2×
“…data notwithstanding, it should be noted that antiangiogenic therapy with bevacizumab has failed to prolong survival in desmoplastic tumours such as breast and pancreatic cancer 3 , casting doubt on a possible antiangiogenic mechanism for the benefits observed with angiotensin inhibitors.”
Self-citationChauhan, V. P., Stylianopoulos, T., Martin, J. D., Popović, Z., Chen, O., Kamoun, W. S., Bawendi, M. G., Fukumura, D., & Jain, R. K. (2012) · Nature Nanotechnology · doi:10.1038/nnano.2012.45 · Cited by 1,101
Self-citationCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943 · cited 6×
“Both hyaluronan and collagen fibres contribute to solid stress in tumours: hyaluronan does so by resisting compression, whereas collagen does so by resisting tension and confining the local microenvironment 5 .”
InfluentialSelf-citationSolid stress inhibits the growth of multicellular tumor spheroids
Helmlinger, G., Netti, P. A., Lichtenbeld, H. C., Melder, R. J., & Jain, R. K. (1997) · Nature Biotechnology · doi:10.1038/nbt0897-778 · Cited by 859 · cited 1×
“Solid stress (pressure from solid tissue components) accumulates in tumours as cancer and stromal cells proliferate in a confined microenvironment created by crosslinked matrix molecules 4–6 .”
Self-citationEffects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor
Ichiki, T., Labosky, P. A., Shiota, C., Okuyama, S., Imagawa, Y., Fogo, A., Niimura, F., Ichikawa, I., Hogan, B. L. M., & lnagami, T. (1995) · Nature · doi:10.1038/377748a0 · Cited by 858
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857 · cited 2×
“The matrix stores and transmits this stress throughout the tumour 7 , collapsing blood vessels to limit perfusion 8,9 .”
Self-citation
Cited by
Items 101–200 of 1,000
Hessmann, E., Patzak, M. S., Klein, L., Chen, N., Kari, V, Ramu, I., Bapiro, T. E., Frese, K. K., Gopinathan, A., Richards, F. M., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-311954 · Cited by 202
“12 – 15 Furthermore, some studies reported stromal ablation on nab-paclitaxel administration in mice and humans suggesting intratumoural nab-paclitaxel sequestration via binding of stromal SPARC to albumin-coated paclitaxel.”
BackgroundChauhan, V. P., Chen, I. X., Tong, R., Ng, M. R., Martin, J. D., Naxerova, K., Wu, M. W., Huang, P., Boucher, Y., Kohane, D. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819889116 · Cited by 206
“AngII/AT1 signaling, for example, regulates blood pressure, and the ARBs that inhibit this signaling can induce hypotension and CAF reprogramming with similar potency (19).”
BackgroundMethodResultInfluentialSelf-citationTumor matrix stiffness promotes metastatic cancer cell interaction with the endothelium
Reid, S. E., Kay, E. J., Neilson, L. J., Henze, A., Serneels, J., McGhee, E. J., Dhayade, S., Nixon, C., Mackey, J. B., Santi, A., et al. (2017) · The EMBO Journal · doi:10.15252/embj.201694912 · Cited by 192
“Furthermore, solid stress within tumors was reduced with an angiotensin inhibitor, resulting in CAF inactivation and reduced collagen and hyaluronan levels, even in established tumor matrices (Chauhan et al , 2013).”
Kharaishvili, G., Simkova, D., Bouchalova, K., Gachechiladze, M., Narsia, N., & Bouchal, J. (2014) · Cancer Cell International · doi:10.1186/1475-2867-14-41 · Cited by 197
“For instance, pancreatic ductal adenocarcinomas, chondrosarcomas, and chordomas are rich in ECM and refractory to chemotherapy [56-58].”
BackgroundPanagi, M., Voutouri, C., Mpekris, F., Papageorgis, P., Martin, M. R., Martin, J. D., Demetriou, P., Pierides, C., Polydorou, C., Stylianou, A., et al. (2020) · Theranostics · doi:10.7150/thno.36936 · Cited by 191
“tumor models treated with common nanomedicines, such as Abraxane and Doxil [20, 22, 35, 36].”
BackgroundMethodInfluentialSelf-citationCurrent Approaches for Improving Intratumoral Accumulation and Distribution of Nanomedicines
Durymanov, M. O., Rosenkranz, A. A., & Sobolev, A. S. (2015) · Theranostics · doi:10.7150/thno.11742 · Cited by 189
Datta, M., Coussens, L. M., Nishikawa, H., Hodi, F. S., & Jain, R. K. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237987 · Cited by 184
Self-citationPancreatic stellate cell: Pandora's box for pancreatic disease biology
Bynigeri, R. R., Jakkampudi, A., Jangala, R., Subramanyam, C., Sasikala, M., Rao, G. V., Reddy, D. N., & Talukdar, R. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i3.382 · Cited by 178
Walking the line: The fate of nanomaterials at biological barriers
Meng, H., Leong, W., Leong, K. W., Chen, C., & Zhao, Y. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.04.056 · Cited by 186
Pirfenidone normalizes the tumor microenvironment to improve chemotherapy
Polydorou, C., Mpekris, F., Papageorgis, P., Voutouri, C., & Stylianopoulos, T. (2017) · Oncotarget · doi:10.18632/oncotarget.15534 · Cited by 185
Self-citationBeyond matrix stiffness: targeting force-induced cancer drug resistance
Kalli, M., Poskus, M. D., Stylianopoulos, T., & Zervantonakis, I. K. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2023.07.006 · Cited by 167
“It was shown that administering mechanotherapeutics, such as pirfenidone, losartan, tranilast, and dexamethasone, reduces tumor stiffness and mechanical forces, and increases tumor perfusion and drug delivery in preclinical tumor models of pancreatic and breast cancer [125,126,130–132].”
BackgroundSelf-citationReengineering the Tumor Microenvironment to Alleviate Hypoxia and Overcome Cancer Heterogeneity
Martin, J. D., Fukumura, D., Duda, D. G., Boucher, Y., & Jain, R. K. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a027094 · Cited by 175
“They also showed that solid stress is stored as strain energy in the ECM, of which collagen fibers and hyaluronan collaborate to transmit the strain energy as solid stress to compress blood and lymphatic vessels (Stylianopoulos et al. 2012, 2013; Chauhan et al. 2013; Jain et al. 2014).”
BackgroundInfluentialSelf-citationEngineered strategies to enhance tumor penetration of drug-loaded nanoparticles
Souri, M., Soltani, M., Moradi Kashkooli, F., & Kiani Shahvandi, M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.11.024 · Cited by 178
Pancreatic cancer: Stroma and its current and emerging targeted therapies
Kota, J., Hancock, J., Kwon, J., & Korc, M. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.12.035 · Cited by 173
Zhang, F., Ma, Y., Li, D., Wei, J., Chen, K., Zhang, E., Liu, G., Chu, X., Liu, X., Liu, W., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01600-2 · Cited by 212
“Earlier studies have demonstrated a role of chlorosartan in limiting the activation of CAFs through inhibiting TGF-β, thereby reducing CAFs-mediated secretion of ECM components, such as hyaluronic acid and collagen, to enhance drug delivery and immunotherapy efficacy [245].”
BackgroundHuang, D., Sun, L., Huang, L., & Chen, Y. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020124 · Cited by 176
“Reduced blood flow directly limits the perfusion of nanoparticles into the tumor site [164].”
BackgroundTherapeutic Effect of Camel Milk and Its Exosomes on MCF7 Cells In Vitro and In Vivo
Badawy, A. A., El-Magd, M. A., & AlSadrah, S. A. (2018) · Integrative Cancer Therapies · doi:10.1177/1534735418786000 · Cited by 169
“Cancer cells have the ability to initiate inflammation through direct production of cytokines(35) or through physical damage to normal tissue.(36) Inflammation plays a crucial role in tumor progression from initiation to the metastatic process.”
BackgroundMolecular Mechanisms and Emerging Therapeutic Targets of Triple-Negative Breast Cancer Metastasis
Neophytou, C., Boutsikos, P., & Papageorgis, P. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00031 · Cited by 173
Leveraging Physiology for Precision Drug Delivery
Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169
“To overcome the IFP barrier, strategies targeting the IFP inducing factors were demonstrated, such as reducing angiogenesis by blocking VEGF (188, 417) and reducing collagen density in the extracellular matrix (52).”
MethodKubota, S., & Takigawa, M. (2015) · Clinical Science · doi:10.1042/cs20140264 · Cited by 166
The Solid Mechanics of Cancer and Strategies for Improved Therapy
Stylianopoulos, T. (2017) · Journal of Biomechanical Engineering · doi:10.1115/1.4034991 · Cited by 169
“Preclinical studies in mice bearing breast and pancreatic tumors have shown that only a 20–40% of the tumor blood vessels are perfused with the rest of them being nonfunctional [9,62].”
BackgroundSelf-citationRepurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
Pantziarka, P. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.521 · Cited by 165
“There is also increasing evidence that existing microtubule disrupting agents used at low or metronomic doses, including the taxanes and vinca alkaloids, exert a positive immunomodulatory action that may help to reverse the immunosuppressive effect of cancer [33–36].”
BackgroundRole of pancreatic stellate cells in chemoresistance in pancreatic cancer
McCarroll, J. A., Naim, S., Sharbeen, G., Russia, N., Lee, J., Kavallaris, M., Goldstein, D., & Phillips, P. A. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00141 · Cited by 175
“More recently, in an elegant and comprehensive study by Chauhan et al. (2013), the angiotensin II Type 1 receptor inhibitor losartan was found to reduce stromal collagen and hyaluronan production, as well as decrease the number of αSMA positive PSCs in orthotopic pancreatic tumors.”
BackgroundShim, M. K., Yang, S., Sun, I., & Kim, K. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114177 · Cited by 173
Hu, Q., Zhu, Y., Mei, J., Liu, Y. L., & Zhou, G. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01717-y · Cited by 181
“The renin-angiotensin system (RAS) inhibitors which are typically used to treat hypertension can attenuate matrix remodeling by inhibiting ECM deposition, LOX expression and COL production [340].”
Elahi-Gedwillo, K. Y., Carlson, M., Zettervall, J., & Provenzano, P. P. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-1334 · Cited by 153
“As PDA progresses from preinvasive PanINs to invasive disease, an increasingly robust stromal environment develops, effectively preventing therapeutic distribution (4,9,12,33).”
BackgroundInfluentialModulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery
Zhang, B., Hu, Y., & Pang, Z. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00952 · Cited by 152
“Therefore, strategies by using low dose of a TGF-β inhibitor, LY364947 was developed to reduce the pericyte coverage of endothelium and increase size gaps between endothelium to increase therapeutic benefits of gemcitabine-loaded liposomes for pancreatic cancer (Cabral et al., 2011; Meng et al., 2013) and Doxil for di…”
BackgroundInfluentialExtracellular Matrix Cues Regulate Mechanosensing and Mechanotransduction of Cancer Cells
Mierke, C. T. (2024) · Cells · doi:10.3390/cells13010096 · Cited by 146
Digesting a Path Forward: The Utility of Collagenase Tumor Treatment for Improved Drug Delivery
Dolor, A., & Szoka, F. C. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00319 · Cited by 145
Incio, J., Suboj, P., Chin, S. M., Vardam-Kaur, T., Liu, H., Hato, T., Babykutty, S., Chen, I., Deshpande, V., Jain, R. K., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0141392 · Cited by 144
“We and others have previously shown that reprogramming the central instigator of the desmoplastic microenvironment—PSCs—can be an effective intervention in the treatment of PDACs [43, 61, 74].”
BackgroundSelf-citationTargeting Pancreatic Stellate Cells in Cancer
Schnittert, J., Bansal, R., & Prakash, J. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.01.001 · Cited by 159
Hou, L., Chen, D., Wang, R., Wang, R., Zhang, H., Zhang, Z., Nie, Z., & Lu, S. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202014397 · Cited by 142
Perez, V. M., Kearney, J. F., & Yeh, J. J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751311 · Cited by 143
Hu, C. T., Liu, X., Ran, W., Meng, J., Zhai, Y., Zhang, P., Yin, Q., Yu, H., Zhang, Z., & Li, Y. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.08.009 · Cited by 148
Perfluorocarbon regulates the intratumoural environment to enhance hypoxia-based agent efficacy
Wang, W., Cheng, Y., Yu, P., Wang, H., Zhang, Y., Xu, H., Ye, Q., Yuan, A., Hu, Y., & Wu, J. (2019) · Nature Communications · doi:10.1038/s41467-019-09389-2 · Cited by 139
Fibroblasts in the Tumor Microenvironment
Truffi, M., Sorrentino, L., & Corsi, F. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-37184-5_2 · Cited by 154
Papageorgis, P., Polydorou, C., Mpekris, F., Voutouri, C., Agathokleous, E., Kapnissi-Christodoulou, C. P., & Stylianopoulos, T. (2017) · Scientific Reports · doi:10.1038/srep46140 · Cited by 138
Self-citationRedundant angiogenic signaling and tumor drug resistance
Gacche, R. N., & Assaraf, Y. G. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.01.002 · Cited by 144
Ager, E. I., Kozin, S. V., Kirkpatrick, N. D., Seano, G., Kodack, D. P., Askoxylakis, V., Huang, Y., Goel, S., Snuderl, M., Muzikansky, A., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv017 · Cited by 136
Self-citationMartin, J. D., Panagi, M., Wang, C., Khan, T. T., Martin, M. R., Voutouri, C., Toh, K., Papageorgis, P., Mpekris, F., Polydorou, C., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b07865 · Cited by 137
Self-citationFu, Y., Liu, S., Zeng, S., & Shen, H. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0815-z · Cited by 138
“The item ‘solid stress’ refers to the physical forces caused by solid and elastic elements of the extracellular matrix and cells [90, 91].”
BackgroundMatrix control of pancreatic cancer: New insights into fibronectin signaling
Topalovski, M., & Brekken, R. A. (2016) · Cancer Letters · doi:10.1016/j.canlet.2015.12.027 · Cited by 132
“For example, inhibition of the hormone angiotensin by losartan was shown to decrease ECM production and consequently increase vascular perfusion [46].”
BackgroundYoshida, G. J., Azuma, A., Miura, Y., & Orimo, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20092256 · Cited by 126
Development of individualized anti-metastasis strategies by engineering nanomedicines
He, Q., Guo, S., Qian, Z., & Chen, X. S. (2015) · Chemical Society Reviews · doi:10.1039/c4cs00511b · Cited by 133
Xin, Y., Li, K., Huang, M. L., Liang, C., Siemann, D. W., Wu, L., Tan, Y., & Tang, X. (2023) · Oncogene · doi:10.1038/s41388-023-02844-x · Cited by 149
“These are all highly relevant to tumor biophysics discussed in this review and each deserves to be the subject of additional reviews.”
BackgroundVoutouri, C., Polydorou, C., Papageorgis, P., Gkretsi, V., & Stylianopoulos, T. (2016) · Neoplasia · doi:10.1016/j.neo.2016.10.001 · Cited by 139
“, Natick, MA) to avoid any associated bias [3,23].”
BackgroundMethodResultSelf-citationPancreatic cancer and its stroma: A conspiracy theory
Xu, Z., Pothula, S. P., Wilson, J. S., & Apte, M. V. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i32.11216 · Cited by 144
Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy
Gkretsi, V., Stylianou, A., Papageorgis, P., Polydorou, C., & Stylianopoulos, T. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00214 · Cited by 123
“Meanwhile, pharmacological treatment of mice is usually administered either orally, using gavage needles directly in the digestive tube, or by intraperitoneal injection or by intravenous injection or by retro-orbital injection (23, 108, 109, 116).”
BackgroundMethodInfluentialSelf-citationEngineered Nanomaterials: The Challenges and Opportunities for Nanomedicines
Albalawi, F., Hussein, M. Z., Fakurazi, S., & Masarudin, M. J. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s288236 · Cited by 137
Vascular Normalization: A New Window Opened for Cancer Therapies
Yang, T., Xiao, H., Liu, X., Wang, Z., Zhang, Q., Wei, N., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719836 · Cited by 141
Ferrara, B., Pignatelli, C., Cossutta, M., Citro, A., Courty, J., & Piemonti, L. (2021) · Cancers · doi:10.3390/cancers13174442 · Cited by 145
Wang, H., Guo, Y., Wang, C., Jiang, X., Liu, H., Yuan, A., Yan, J., Hu, Y., & Wu, J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2020.120621 · Cited by 124
Self-citationErstad, D. J., Sojoodi, M., Taylor, M. S., Ghoshal, S., Razavi, A. A., Graham‐O'Regan, K. A., Bardeesy, N. M., Ferrone, C. R., Lanuti, M. D., Caravan, P. D., et al. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.034793 · Cited by 133
Belle, J. I., Sen, D., Baer, J. M., Liu, X., Lander, V. E., Ye, J., Sells, B. E., Knolhoff, B. L., Ahmad, F. F., Kang, L., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0428 · Cited by 137
Key role of pancreatic stellate cells in pancreatic cancer
Pothula, S. P., Xu, Z., Goldstein, D., Pirola, R. C., Wilson, J. S., & Apte, M. V. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.035 · Cited by 131
Ultrasound and microbubbles to beat barriers in tumors: Improving delivery of nanomedicine
Snipstad, S., Vikedal, K., Maardalen, M., Kurbatskaya, A., Sulheim, E., & Davies, C. D. L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113847 · Cited by 127
Towards extracellular matrix normalization for improved treatment of solid tumors
Abyaneh, H. S., Regenold, M., McKee, T. D., Allen, C. J., & Gauthier, M. A. (2020) · Theranostics · doi:10.7150/thno.39995 · Cited by 128
“Overall, the inhibition of TGF-β signaling has been shown to be effective in enhancing the penetration of small-molecule drugs and nano-formulations into tumors [116, 117].”
BackgroundCancer Extracellular Matrix Proteins Regulate Tumour Immunity
Gordon-Weeks, A. N., & Yuzhalin, A. E. (2020) · Cancers · doi:10.3390/cancers12113331 · Cited by 132
Reengineering the Tumor Vasculature: Improving Drug Delivery and Efficacy
Stylianopoulos, T., Munn, L. L., & Jain, R. K. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.02.010 · Cited by 119
Self-citationHypoxia signaling in cancer: Implications for therapeutic interventions
Zhuang, Y., Liu, K., He, Q., Gu, X., Jiang, C., & Wu, J. (2023) · MedComm · doi:10.1002/mco2.203 · Cited by 119
Cancer-associated fibroblasts: key determinants of tumor immunity and immunotherapy
Barrett, R., & Puré, E. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.03.004 · Cited by 117
“These include vitamin D ligands [85], which reprogram CAFs to a more quiescent-like state, and angiotensin inhibitors [86], which influence CAF matrix deposition, decompressing the tumor, improving its vasculature, and thus making it more susceptible to chemo and immunotherapy.”
BackgroundAntifibrotic therapy to normalize the tumor microenvironment
Hauge, A., & Rofstad, E. K. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02376-y · Cited by 114
Aguilera, K. Y., Huang, H., Du, W., Hagopian, M. M., Wang, Z., Hinz, S., Hwang, T. H., Wang, H., Fleming, J. B., Castrillon, D. H., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0834 · Cited by 118
“These data support the premise that collagen-mediated activation of DDR1 induces a signal pathway that includes PEAK1, SRC, and PYK2, which in turn are potentially responsible for collagen-induced chemoresistance (3, 39) and tumor progression.”
BackgroundNanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy
Zhu, Y., Yu, X., Thamphiwatana, S., Zheng, Y., & Pang, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.08.010 · Cited by 118
Photosensitizer Nanoparticles Boost Photodynamic Therapy for Pancreatic Cancer Treatment
Yang, H., Liu, R., Xu, Y., Qian, L., & Dai, Z. (2021) · Nano-Micro Letters · doi:10.1007/s40820-020-00561-8 · Cited by 125
Song, Y., Kim, S.-H., Kim, K. M., Choi, E. K., Kim, J., & Seo, H. R. (2016) · Scientific Reports · doi:10.1038/srep36750 · Cited by 114
Voutouri, C., Mpekris, F., Papageorgis, P., Odysseos, A. D., & Stylianopoulos, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104717 · Cited by 126
Self-citationMpekris, F., Angeli, S. I., Pirentis, A. P., & Stylianopoulos, T. (2015) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-015-0682-0 · Cited by 123
“Furthermore, vessel compression reduces blood flow, which decreases the delivery of drugs compromising therapeutic outcomes (Chauhan et al. 2013; Jain 2013, 2014; Jain et al. 2014).”
BackgroundSelf-citationCun, X., Ruan, S., Chen, J., Zhang, L., Li, J., He, Q., & Gao, H. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.12.002 · Cited by 117
Panagi, M., Mpekris, F., Chen, P., Voutouri, C., Nakagawa, Y., Martin, J. D., Hiroi, T., Hashimoto, H., Demetriou, P., Pierides, C., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34744-1 · Cited by 111
Self-citationThe extracellular matrix in hepatocellular carcinoma: Mechanisms and therapeutic vulnerability
Roy, A. M., Iyer, R. V., & Chakraborty, S. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101170 · Cited by 152
Turning cold tumors into hot tumors to ignite immunotherapy
Liu, Y., Wang, Y., Wang, S., Li, J., He, W. A., Fan, X.-J., & Wan, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02477-6 · Cited by 136
Nanomedicine Penetration to Tumor: Challenges, and Advanced Strategies to Tackle This Issue
Munir, M. U. (2022) · Cancers · doi:10.3390/cancers14122904 · Cited by 121
“tumor penetration of nanoparticles becomes hindered [23,24].”
BackgroundTumor extracellular matrix modulating strategies for enhanced antitumor therapy of nanomedicines
Li, M., Zhang, Y., Zhang, Q., & Li, J. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100364 · Cited by 124
“Therefore, suppression of CAF activity can lead to inhibition of tumor ECM production, thus contributing to improved penetration of drugs and nanotherapeutics for enhanced cancer chemotherapy [48].”
BackgroundNew Strategies in Cancer Nanomedicine
Tong, R., & Kohane, D. S. (2015) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103456 · Cited by 113
Chen, X., Jia, F., Li, Y., Deng, Y., Huang, Y., Liu, W., Jin, Q., & Ji, J. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.119999 · Cited by 110
Peppis, P. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107337206 · Cited by 109
Linke, J. A., Munn, L. L., & Jain, R. K. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00745-z · Cited by 132
“Three drugs that have been tested preclinically for alleviation of solid stress are losartan, tranilast and pirfenidone 54–56 , 184 .”
InfluentialSelf-citationZhang, L., Wang, Y., Yang, Y., Liu, Y., Ruan, S., Zhang, Q., Tai, X., Chen, J., Xia, T., Qiu, Y., et al. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5b01473 · Cited by 107
Stars and stripes in pancreatic cancer: role of stellate cells and stroma in cancer progression
Wilson, J. S., Pirola, R. C., & Apte, M. V. (2014) · Frontiers in Physiology · doi:10.3389/fphys.2014.00052 · Cited by 120
“Similarly, using losartan (another Angiotensin II receptor inhibitor), Chauhan et al. (2013) have reported decreased αSMA positive cells, and reduced collagen and hyaluronan production in the stroma of pancreatic cancer in an orthotopic mouse model. ii.”
Dhaliwal, A., & Zheng, G. (2019) · Theranostics · doi:10.7150/thno.37204 · Cited by 103
“Hormonal effectors, such as the angiotensin II receptor antagonist losartan, can capitalize on these principles as well – in this case, its action decompresses tumor vessels, increases tumor perfusion, and suppresses collagen synthesis, leading to enhanced drug accumulation [36,37].”
BackgroundStroma-Targeting Therapy in Pancreatic Cancer: One Coin With Two Sides?
Jiang, B., Zhou, L., Lu, J., Wang, Y., Liu, C., You, L., & Guo, J. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.576399 · Cited by 93
“In addition, the repurposing of antihypertensive drugs targeting the renin-angiotensin pathway can reprogram CAFs towards normalizing ECM by inhibiting TGF-b (59, 60).”
BackgroundInfluentialMpekris, F., Panagi, M., Voutouri, C., Martin, J. D., Samuel, R., Takahashi, S., Gotohda, N., Suzuki, T., Papageorgis, P., Demetriou, P., et al. (2021) · Advanced Science · doi:10.1002/advs.202001917 · Cited by 102
Self-citationBaronzio, G., Parmar, G., & Baronzio, M. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00165 · Cited by 98
“This result is achieved using antagonists against the angiotensin II receptors (110).”
BackgroundMpekris, F., Papageorgis, P., Polydorou, C., Voutouri, C., Kalli, M., Pirentis, A. P., & Stylianopoulos, T. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.06.022 · Cited by 101
Self-citationLiu, Y., Zhou, J., Li, Q., Li, L., Jia, Y., Geng, F., Zhou, J., & Yin, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.02.019 · Cited by 102
Vaish, U., Jain, T., Are, A. C., & Dudeja, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413408 · Cited by 111
“This can improve blood flow and drug delivery to tumors, while decreasing the density of activated αSMA+ CAFs [90,91].”
BackgroundKim, D. K., Jeong, J., Lee, D. S., Hyeon, D. Y., Park, G. W., Jeon, S., Lee, K. B., Jang, J., Hwang, D., Kim, H. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33991-6 · Cited by 118
Qin, Q., Yu, R., Eriksson, J., Tsai, H., & Zhu, H. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216859 · Cited by 112
Coulson, R., Liew, S. H., Connelly, A. A., Yee, N. S., Deb, S., Kumar, B., Vargas, A. C., O’Toole, S. A., Parslow, A. C., Poh, A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15553 · Cited by 96
Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis
Subhan, M. A., Parveen, F., Filipczak, N., Yalamarty, S. S. K., & Torchilin, V. P. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030389 · Cited by 98
Parallel Accumulation of Tumor Hyaluronan, Collagen, and Other Drivers of Tumor Progression
Li, X., Shepard, H. M., Cowell, J. A., Zhao, C., Osgood, R. J., Rosengren, S., Blouw, B., Garrovillo, S. A., Pagel, M. D., Whatcott, C. J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3284 · Cited by 99
“Collagen has long been associated with hypoxia (10, 61) and highly desmoplasmic tumors, such as pancreatic cancer.”
BackgroundAngiotensins as therapeutic targets beyond heart disease
Passos-Silva, D. G., Brandan, E., & Santos, R. A. S. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.03.001 · Cited by 99
Liu, H., Naxerova, K., Pinter, M., Incio, J., Lee, H., Shigeta, K., Ho, W. W., Crain, J. A., Jacobson, A., Michelakos, T., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0256 · Cited by 96
“Consequently, hypoxia is relieved and the efficacy of chemotherapeutic drugs, oncolytic viruses, or vaccine therapy is significantly enhanced (5, 6, 29).”
BackgroundInfluentialSelf-citationRenin–Angiotensin–Aldosterone System and Immunomodulation: A State-of-the-Art Review
Laghlam, D., Jozwiak, M., & Nguyen, L. S. (2021) · Cells · doi:10.3390/cells10071767 · Cited by 96
“These observations illustrate the role of RAS in tumorigenesis and suggest a potential synergistic role of RASBs in cancer treatment: tumor progression may be slowed down through inhibition of proliferation and neovascularization, promotion of tumor cell apoptosis, and enhancement of anti-cancer drug delivery [52].”
BackgroundSong, K., Yu, Z., Zu, X., Li, G., Hu, Z., & Xue, Y. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810509 · Cited by 105
Quantifying solid stress and elastic energy from excised or in situ tumors
Nia, H. T., Datta, M., Seano, G., Huang, P., Munn, L. L., & Jain, R. K. (2018) · Nature Protocols · doi:10.1038/nprot.2018.020 · Cited by 101
Self-citationTrials and tribulations of pancreatic cancer immunotherapy
Principe, D. R., Korc, M., Kamath, S. D., Munshi, H. G., & Rana, A. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.01.031 · Cited by 100
Solid stress impairs lymphocyte infiltration into lymph-node metastases
Jones, D., Wang, Z., Chen, I. X., Zhang, S., Banerji, R., Lei, P., Zhou, H., Xiao, V., Kwong, C., van Wijnbergen, J. W., et al. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00766-1 · Cited by 98
Self-citationAccumulation of mechanical forces in tumors is related to hyaluronan content and tissue stiffness
Voutouri, C., & Stylianopoulos, T. (2018) · PLoS ONE · doi:10.1371/journal.pone.0193801 · Cited by 95
Self-citation
Metadata
- Authors
- Chauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., Popović, Z., Huang, P., Bawendi, M. G., Boucher, Y., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Massachusetts Institute of Technology (US)
- Corresponding author
- Jain, Rakesh K.
- ORCID
- Venue
- Nature Communications
- Published
- 2013-10-01
- Volume
- 4
- Issue
- 1
- Pages
- 2516-2516
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC3806395
- OpenAlex
- W1603491949
- Cited by
- 1,031
- References
- 64
- Citations by year
- 2026: 85 · 2025: 77 · 2024: 86 · 2023: 101 · 2022: 96 · 2021: 128 · 2020: 92 · 2019: 82 · 2018: 66 · 2017: 69 · 2016: 56 · 2015: 54 · 2014: 31 · 2013: 7
- FWCI
- 21.97
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Nature Communications (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-nd)
- PMC
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- Lustgarten Foundation
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology
- National Institutes of Health (1s10rr027070-01, W81XWH, CA080124, CA085140)
- National Cancer Institute (R01CA115767, W81XWH-10-1-0016, T32CA073479, R01CA085140, P01-CA126642, R01-CA11576, P01CA080124, R01CA126642, R01CA098706)
- National Institute of Biomedical Imaging and Bioengineering (P41EB015903)
- National Center for Research Resources (S10-RR027070)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- losartan, hyaluronic acid, tumor stroma, solid stress, collagen, TGF-β1, connective tissue growth factor, endothelin-1, drug delivery, tumor hypoxia, chemotherapy potentiation, breast cancer, pancreatic cancer, drug repurposing
- MeSH terms
- Angiotensins, Animals, Antineoplastic Agents, Collagen, Drug Synergism, Female, Fluorouracil, Humans, Hyaluronic Acid, Mammary Neoplasms, Experimental, Pancreatic Neoplasms, Stress, Mechanical, Cell Hypoxia, Gene Expression Regulation, Neoplastic, Stromal Cells, Endothelin-1, Losartan, Mechanotransduction, Cellular, Receptor, Angiotensin, Type 1, Angiotensin II Type 1 Receptor Blockers, Mice, Transforming Growth Factor beta1, Connective Tissue Growth Factor, Drug Repositioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.